CLINICAL TRIAL IS A CRITICAL STEP IN TESTING WHETHER CELLIANT® CAN POSITIVELY IMPACT DIABETIC PATIENTS WITH VASCULAR IMPAIRMENT

 » 10th Peer-Reviewed Study of CELLIANT®, the Flagship Product of Hologenix, a Materials Science Innovation Company, Published in Journal of Textile Science & Engineering, More Research on the Horizon »

The diabetic community has always been a priority for Hologenix, creators of CELLIANT® infrared technology, so the company embarked on an initial study to test the hypothesis that the technology can positively impact diabetic patients with vascular impairment, now published in the Journal of Textile Science & Engineering. Another study is underway as well with more research on the horizon.

According to statistics cited in the International Diabetes Federation Diabetes Atlas, 9th edition, globally, close to a half billion people are living with diabetes and that number is expected to increase by more than 50 percent in the next 25 years.

The introduction of the study in the Journal of Textile Science & Engineering also reports that diabetic patients frequently suffer from a combination of peripheral neuropathy and peripheral artery disease, which particularly affects their feet. It further states that it has been estimated that the lifetime risk for the development of foot ulcers in diabetic patients can be as high as 25 percent and that the risk of amputation is 10 to 20 times higher than in non-diabetic subjects.

The study was performed by Lawrence A. Lavery, D.P.M., M.P.H., a Professor in the Department of Plastic Surgery at UT Southwestern Medical Center. His clinic and research interests involve diabetic foot complications, infections, and wound healing, and he participated in the conception, design, implementation, and authorship of the Journal of Textile Science & Engineering study. 

CELLIANT technology is a patented process for adding micron-sized thermo-responsive mineral particles to fibers, in this case, polyethylene terephthalate (PET) fibers. The resulting CELLIANT yarns were woven into stockings and gloves containing either 82% CELLIANT polyester, 13% nylon, and 5% spandex or for the placebo, 82% polyester with no CELLIANT, 13% nylon, and 5% spandex. CELLIANT products absorb body heat and re-emit the energy back to the body as infrared energy, which is non-invasive and increases temporary blood flow and cell oxygenation levels in the body.

The objective of the study was to “evaluate changes in transcutaneous oxygen (TcPO2) and peripheral blood flow (laser Doppler, LD) in the hands and feet of diabetic patients with vascular impairment when CELLIANT gloves and stockings are worn.” While there was not a statistically significant result across all subjects, the study did show that some patients wearing CELLIANT stockings for 60 minutes had an increase of as much as 20% in tissue oxygenation and 30% in localized blood flow. According to the study’s conclusion, “the trends that were observed in favor of CELLIANT stockings suggest that a larger well-designed clinical trial should be undertaken and may provide evidence of clinical efficacy in the treatment of the diabetic foot.”

The study also notes that “There have been no documented or observed side effects of wearing CELLIANT stockings, and they are relatively inexpensive compared to conventional pharmaceutical interventions.” 

Hologenix has embarked on a more comprehensive trial, “Study to Evaluate CELLIANT Diabetic Medical Socks to Increase Tissue Oxygenation and Incidence of Complete Wound Closure in Diabetic Foot Wounds” – NCT04709419, which focuses on the impact of CELLIANT technology to potentially improve tissue oxygenation and wound healing outcomes.
 

“We are excited to explore whether future studies of infrared, with its most common biological effects of increased localized blood flow and cellular oxygenation, could result in a breakthrough in diabetic patients with vascular impairment,” said Seth Casden, Hologenix Co-founder and CEO. “We see a huge potential opportunity with this research for helping to fulfill our core mission of improving people’s health and well-being by potentially reducing the impact of diabetes, and we are actively seeking partners to expand our research efforts.”

About Hologenix

Hologenix, LLC, headquartered in Pacific Palisades, California, is a materials science company innovating products that energize all aspects of life. Its flagship innovation, CELLIANT®, is a science-backed infrared (IR) technology that improves health and wellness by promoting restful sleep and enhancing performance and recovery. CELLIANT’s natural blend of IR-generating minerals is embedded into fibers, yarns, and fabrics, powering responsive textiles. CELLIANT is a key ingredient used by world-class brands in products spanning apparel, sleepwear, bedding, upholstery, uniforms, and medical supplies.

CELLIANT is rigorously tested by a Science Advisory Board composed of experts in photobiology, nanotechnology, sleep medicine, and diabetes and wound care. The Science Advisory Board has overseen 10 peer-reviewed published studies that demonstrate CELLIANT’s effectiveness and the benefits of infrared energy. For more information, visit celliant.com.

Link to the research study in the Journal of Textile Science & Engineering:  https://www.hilarispublisher.com/author/lawrence-a-lavery-28490